Scientists take big step toward stopping cancer metastasis

February 8, 2018, The Scripps Research Institute
Left: The robust network of fully dilated, angiogenic blood vessels (red) within a primary tumor, which developed from LTBP3-competent epidermoid carcinoma cells (green). Right: In contrast, the LTBP3-deficient tumors develop thinner, collapsed vessels, which are incapable of efficiently supporting cancer cell dissemination. Credit: Elena Deryugina and James P. Quigley

New research from The Scripps Research Institute (TSRI) may give scientists a chance to target tumors before they metastasize. The study, published recently in the Nature research journal Oncogene, shows that a protein called LTBP3 fuels a chain reaction that leads some early developing tumors to grow new blood vessels. These vessels then act like highways to spread cancer cells throughout the body, seeding metastatic tumors very early on.

"Lower LTBP3 levels appear to be associated with better prognosis in patients with certain types of ," says Elena Deryugina, PhD, an assistant professor at TSRI and first author of the new study. Deryugina led the collaborative study with senior authors James P. Quigley, PhD, a TSRI professor, and Daniel Rifkin, PhD, a professor at NYU School of Medicine.

Their research addresses a long-standing challenge in medicine. Over the years, a potent growth factor molecule called TGFβ has caught the eye of many cancer researchers. TGFβ has multiple roles in healthy people and in disease, and it can be both a promoter and suppresser of cell growth. Although TGFβ has been a tempting cancer therapy target for a long time, scientists still do not know know how to dampen its harmful effects without interfering with its normal roles in the body.

As long-time collaborators, Deryugina and Quigley have led research that shows that the initial steps of tumor metastasis can occur when a is barely detectable. This work sparked their interest in the role of LTBP3, short for Latent TGFβ Binding Protein 3. They knew that LTBP3 partners with TGFβ to regulate its secretion, activation and maturation, but wondered what else LTBP3 might control.

Could LTBP3 set TGFβ on its harmful path of action in early-stage tumors, and might LTBP3 have its own role, independent of TGFβ, in cancer metastasis?

TSRI scientists take big step toward stopping cancer metastasis
This curve shows a dramatic difference in survival between head and neck cancer patients with high LTBP3 expression levels (green) and low expression levels (blue). Researchers believe LTBP3 levels, detectable before cancer reaches stage 4, may be an indicator of patient outcomes in this particular cancer type. Credit: Elena Deryugina and James P. Quigley

Researchers used chick embryo tumor models and a rodent model of head and neck cancer to discover how LTBP3 is involved in the spread of aggressive . They knocked down LTBP3 expression and secretion in human tumor cell lines representing carcinoma, head and neck carcinoma and a fibrosarcoma. In each model, the team found that without LTBP3, primary tumor could not metastasize efficiently.

"Our experimental findings showed that LTBP3 is active in the very early steps of metastatic spread," says Quigley.

"Specifically, LTBP3 appears to help tumors grow new blood vessels in a process called angiogenesis, which is critical for tumor cell intravasation. That is when cancer cells enter into blood vessels of defined size and permeability," adds Deryugina.

Importantly, the new data is in line with clinical findings that LTBP3 levels can indicate better overall survival in cancer patients with early-stage head and neck carcinomas.

Taken together, these findings suggest LTBP3 may be a good "upstream" drug target to treat early stage tumors without affecting more complex roles of TGFβ in other parts of the body.

Researchers next plan to investigate precisely how LTBP3 and TGFβ biochemically partner in the induction of new blood vessels deep within a tumor.

Explore further: Study suggests tumors may 'seed' cancer metastases earlier than expected

More information: Elena I. Deryugina et al, LTBP3 promotes early metastatic events during cancer cell dissemination, Oncogene (2018). DOI: 10.1038/s41388-017-0075-1

Related Stories

Study suggests tumors may 'seed' cancer metastases earlier than expected

October 29, 2015
A new study from scientists at The Scripps Research Institute (TSRI) helps explain why cancer metastasis is so hard to stop.

At last, a clue to where cancer metastases are born

May 2, 2017
Even in remission, cancer looms. Former cancer patients and their doctors are always on alert for metastatic tumors. Now scientists at The Scripps Research Institute (TSRI) have discovered why some cancers may reoccur after ...

Gene-modified, virus-specific T cell therapy shows promise in treating lymphoma, with little toxicity

January 26, 2018
In a first-of-its-kind clinical study, Baylor College of Medicine evaluated the safety, survival and anti-tumor activity of tumor-specific T cells rendered resistant to transforming growth factor β (TGFβ), in patients with ...

New study provides important insight into how tumors metastasize

August 23, 2016
Research has shown that the growth of cancerous tumours is affected by transforming growth factor (TGFβ) in the body's cells; TGFβ both suppresses and stimulates tumour development. But it has not been understood how this ...

Starving tumors: New target discovered

January 24, 2018
Actively growing tumors have a high demand for oxygen and nutrients. Therefore, they stimulate the growth of blood vessels through a process called angiogenesis. If tumor-associated angiogenesis is suppressed, it may limit ...

Researchers identify a potential molecular trigger for invasiveness in prostate cancer cells

November 21, 2017
A small protein modification can trigger the aggressive migratory and invasive properties of prostate cancer cells, according to new research published on the cover of Oncotarget. The findings give greater insight into how ...

Recommended for you

Stem cell vaccine immunizes lab mice against multiple cancers

February 15, 2018
Stanford University researchers report that injecting mice with inactivated induced pluripotent stem cells (iPSCs) launched a strong immune response against breast, lung, and skin cancers. The vaccine also prevented relapses ...

Induced pluripotent stem cells could serve as cancer vaccine, researchers say

February 15, 2018
Induced pluripotent stem cells, or iPS cells, are a keystone of regenerative medicine. Outside the body, they can be coaxed to become many different types of cells and tissues that can help repair damage due to trauma or ...

Team paves the way to the use of immunotherapy to treat aggressive colon tumors

February 15, 2018
In a short space of time, immunotherapy against cancer cells has become a powerful approach to treat cancers such as melanoma and lung cancer. However, to date, most colon tumours appeared to be unresponsive to this kind ...

Can our genes help predict how women respond to ovarian cancer treatment?

February 15, 2018
Research has identified gene variants that play a significant role in how women with ovarian cancer process chemotherapy.

First comparison of common breast cancer tests finds varied accuracy of predictions

February 15, 2018
Commercially-available prognostic breast cancer tests show significant variation in their abilities to predict disease recurrence, according to a study led by Queen Mary University of London of nearly 800 postmenopausal women.

Catching up to brain cancer: Researchers develop accurate model of how aggressive cancer cells move and spread

February 15, 2018
A brief chat at a Faculty Senate meeting put two University of Delaware researchers onto an idea that could be of great value to cancer researchers.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.